{
    "id": 1835,
    "fullName": "CCNE1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CCNE1 over exp indicates an over expression of the Ccne1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 898,
        "geneSymbol": "CCNE1",
        "terms": [
            "CCNE1",
            "CCNE",
            "pCCNE1"
        ]
    },
    "variant": "over exp",
    "createDate": "09/19/2014",
    "updateDate": "12/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8619,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovotine (seliciclib) induced apoptosis and inhibited growth of CCNE1 (cyclin E)-dependent murine lung cancer cell lines in culture, and demonstrated anti-tumor activity in mouse models (PMID: 20028770).",
            "molecularProfile": {
                "id": 1805,
                "profileName": "CCNE1 over exp"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6702,
                    "pubMedId": 20028770,
                    "title": "Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20028770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2377,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovitine (seliciclib), in combination with Alvocidib (flavopiridol) inhibited growth in multiple myeloma cells over expressing CCNE1 (PMID: 22558078).",
            "molecularProfile": {
                "id": 1805,
                "profileName": "CCNE1 over exp"
            },
            "therapy": {
                "id": 2816,
                "therapyName": "Alvocidib + Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3008,
                    "pubMedId": 22558078,
                    "title": "Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22558078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1067,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and AZD0855 acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1520,
                "therapyName": "AZD8055 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1071,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Selumetinib (AZD6244) acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1517,
                "therapyName": "Palbociclib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1060,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Adrucil (fluorouracil) acted synergistically to decrease proliferation and survival of pancreatic cancer cell lines with a loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1509,
                "therapyName": "Fluorouracil + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1068,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Apitolisib (GDC-0980) acted synergistically to decrease proliferation and survival of pancreatic cancer cells with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1516,
                "therapyName": "GDC-0980 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic cancer cell lines with a loss of CDKN2A, upregulation of CCNE1 and CCND1 conferred resistance to Ibrance (palbociclib) treatment in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1066,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and BEZ235 acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1515,
                "therapyName": "BEZ235 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1699,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Pimasertib acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 2016,
                "therapyName": "Palbociclib + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1804,
            "profileName": "CCNE1 over exp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1805,
            "profileName": "CCNE1 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 4837,
                    "name": "CDK2 Inhibitor",
                    "profileName": "CCNE1 over exp"
                }
            ]
        },
        {
            "id": 2398,
            "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}